The Role of ATP in Chronic Cough. Identifying those who may benefit from new anti-cough medications by assessing cough response to ATP and by measuring blood ATP levels

Not Applicable

Suspended

• Conditions: The role of ATP in the mechanism of refractory chronic cough; Respiratory

• Registration Number: ISRCTN11791599
• Lead Sponsor: Manchester University NHS Foundation Trust

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Start: 2021-04-13
• Last Update Posted: 5 August 2022
• Study Completion: 2023-04-01

Recruitment & Eligibility

• Status: Suspended
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

1. Males and females 18 - 80yrs, inclusive
2. Non-smokers; ex-smokers <20 pack years, >6 months abstinence
3. Healthy Volunteers:
3.1. No clinically relevant abnormalities based on the medical history, physical examination, vital signs
3.2. No history of current or significant past respiratory disease, specifically a diagnosis of asthma
3.3. Spirometry within normal limits
4. Chronic Cough Patients :
4.1. Have a refractory chronic cough as defined by BTS/ERS guidelines
4.2. No evidence of asthma during clinical evaluation of chronic cough e.g. elevated FeNO, bronchodilator reversibility, abnormal methacholine responsiveness

Exclusion Criteria

1. Any condition that may increase airway/circulating levels of ATP/adenosine e.g. chronic cardiac failure, chronic hypoxia, and vigorous exercise
2. Pregnancy or Breastfeeding
3. Upper or lower respiratory tract infection or significant change in pulmonary status within 4 weeks of enrolment.
4. Any therapy that may modulate cough (e.g. ACE inhibitors, opioids, gabapentin)
5. Patients with asthma

Study & Design

• Study Type: Interventional
• Study Design: Not specified